A Phase 3 interventional study of Azathioprine and Chloroquine in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 10 sites in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-13.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 67th largest by enrollment, is one of 5 that started in 2013, is one of 47 in phase 3, and was the 75th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 82nd largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2013, is one of 85 in phase 3, and was the 170th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase IIIb, multicenter, open label, single arm study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab as monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants with active rheumatoid arthritis who are either naïve to or have an inadequate response to prior non-biologic or/and biologic DMARDs. The anticipated time on study treatment is 52 weeks. Those participants who will complete the 60-week study period and have achieved Disease Activity Score 28 (DAS28) remission or a good European League Against Rheumatism (EULAR) response at 52 weeks will be eligible to enter the extension phase until tocilizumab is commercially available and reimbursed in Greece.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen at Week 24, participant may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. After Week 52, participants who remain in study will enter a 8 week wash-out period and then (from Week 60) will proceed to the extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.
Drug: Azathioprine · Drug: Chloroquine · Drug: Hydroxychloroquine · Drug: Leflunomide · Drug: Methotrexate · Drug: Sulfasalazine · Drug: Tocilizumab
Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
Also known as: RoActemra, Actemra
Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24
DAS28-ESR score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), patient global assessment of disease activity (PGA) (general health \[GH\]) using visual analog scale (VAS): 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in millimeters per hour \[mm/hr\]). The score is calculated using the following formula: DAS28-ESR = \[0.56 multiplied by (\*) square root (√) of TJC28\] plus (+) \[0.28\*√SJC28\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score of less than (\<) 2.6 represents DAS28-ESR remission.
Time frame: Week 24
Percentage of Participants Who Maintained DAS28-ESR Remission From Week 24 up to Week 52 Among Participants on Tocilizumab Monotherapy Since Week 24
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score \<2.6 represents DAS28-ESR remission. The percentage reported for Week 24 is based on confirmation on switching to SC tocilizumab monotherapy.
Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants Who Achieved DAS28-ESR Remission/Low Disease Activity (LDA) From Week 28 up to Week 52 Among Participants With Intensification of Methotrexate/Other Non-Biologic DMARDs in Combination With Tocilizumab Since Week 24
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score \<2.6 represents DAS28-ESR remission. DAS28-ESR score greater than or equal to (\>/=) 2.6 and \<3.2 represents LDA.
Time frame: Weeks 28, 32, 36, 40, 44, 48, 52
Change From Baseline in DAS28-ESR up to Week 52
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. A negative change from baseline indicates an improvement.
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Number of Participants With American College of Rheumatology 20 (ACR20) Response
ACR20 response was defined as \>/=20% improvement from baseline in both TJC28 and SJC28 as well as in 3 out of 5 additional parameters: Separate patient and physician's global assessment of disease activity on VAS (0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS), patient's assessment of pain on VAS (0 mm=no pain to 100 mm=unbearable pain, displayed on the 100 mm horizontal VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI) (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without any difficulty to 3=unable to do), and acute phase response (ESR in mm/hr, for a total possible score of 0 to 10).
Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Response Criteria
Response to treatment was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the baseline visit. Participants with a score lesser than or equal to (\</=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \</=5.1 with reduction of \>0.6 to \</=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \</=1.2 points, or any score with reduction \</=0.6 points, were assessed as having 'no response'.
Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Change From Baseline in Simplified Disease Activity Index (SDAI) Score up to Week 52
SDAI is an index for measuring disease activity. SDAI is the numerical sum of five outcome parameters: TJC28 and SJC28, PGA and physician global assessment of disease activity assessed on VAS (0 centimeter \[cm\]-10 cm); 0 cm= no disease activity and 10 cm= worst disease activity, and CRP (in milligrams per deciliter \[mg/dL\]). SDAI total score ranges from 0 to 86, with higher scores indicating increased (or severe) disease activity. SDAI score \</=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Change From Baseline in TJC28 up to Week 52
28 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 28. A negative change from baseline indicated improvement.
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Change From Baseline in SJC28 up to Week 52
28 joints were assessed for swelling and joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 28. A negative change from baseline indicated improvement.
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With Corticosteroid Dose Reduction or Discontinuation
Time frame: From Baseline up to Week 52
Number of Participants by Reasons (Categories) for Corticosteroid Dose Reduction or Discontinuation
Reasons for corticosteroid dose reduction included: Safety Reasons (including elevated liver function test results, respiratory infections, infections and infestations, gastrointestinal disorders etc.); Other Reasons (disease remission, improvement etc.); and Unknown Reasons (including no reason). Number of participants by reasons (Safety, Other, Unknown) for corticosteroid dose reduction or discontinuation were reported.
Time frame: From Baseline up to Week 52
Number of Participants With Anti-Tocilizumab Antibodies (ATA)
All samples were tested using a screening assay and, if positive, by a confirmation assay to determine specificity and a neutralizing assay to test for the ability to inhibit the activity of tocilizumab. Number of participants with a positive assay result for screening assay (ATA - Screen), confirmatory assay (ATA - Confirmatory), and neutralizing assay (ATA - Neutralizing) was reported separately.
Time frame: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
Soluble Interleukin-6 Receptor (sIL-6R) Levels
Time frame: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
Tocilizumab Serum Levels
Time frame: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
PGA, Using VAS Score
PGA was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end = 100 mm, and was described as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Patient Assessment of Pain, Using VAS Score
The participant's level of pain was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as "no pain" and the extreme right end = 100 mm, and was described as "unbearable pain". Higher values correspond to worst state of participant (higher level of pain).
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
HAQ-DI Score
The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set were scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person was required. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent "mild to moderate difficulty", 1 to 2 as "moderate to severe disability", and 2 to 3 as "severe to very severe disability".
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants Who Received All Planned Study Medication (Compliance)
Compliance (in terms of percentage of participants who received all planned study medication) was assessed on the basis of participant diary cards and return records.
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score
FACIT-Fatigue total score is sum of FACIT-General subscale score and FACIT-Fatigue (additional concerns) subscale score. FACT-General consists of 27 questions grouped in 4 domains of general health-related quality of life: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-General score ranges between 0-108. FACIT-Fatigue subscale is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). For all items, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue subscale score for a total possible score of 0 (worse score) to 52 (better score). FACIT-Fatigue total score (FACT-G plus FACT-F subscale scores) ranges from 0 (better score) to 160 (worse score).
Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Participants were enrolled in 9 locations in Greece
| Milestone | Tocilizumab |
|---|---|
| Started | 97 |
| Completed | 41 |
| Not completed | 56 |
| Withdrew: Insufficient therapeutic response | 13 |
| Withdrew: Anaphylaxis or serious hypersensitivity | 2 |
| Withdrew: Adverse event | 11 |
| Withdrew: Physician decision | 3 |
| Withdrew: Withdrawal by subject | 17 |
| Withdrew: Lost to follow-up | 10 |
DAS28-ESR score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), patient global assessment of disease activity (PGA) (general health \[GH\]) using visual analog scale (VAS): 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in millimeters per hour \[mm/hr\]). The score is calculated using the following formula: DAS28-ESR = \[0.56 multiplied by (\*) square root (√) of TJC28\] plus (+) \[0.28\*√SJC28\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score of less than (\<) 2.6 represents DAS28-ESR remission.
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24 | 40 |
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score \<2.6 represents DAS28-ESR remission. The percentage reported for Week 24 is based on confirmation on switching to SC tocilizumab monotherapy.
| percentage of participants | Tocilizumab |
|---|---|
| Week 24 | 38.7 |
| Week 28 | 34.2 |
| Week 32 | 36.5 |
| Week 36 | 36.5 |
| Week 40 | 36.5 |
| Week 44 | 35.2 |
| Week 48 | 35.7 |
| Week 52 | 38.8 |
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score \<2.6 represents DAS28-ESR remission. DAS28-ESR score greater than or equal to (\>/=) 2.6 and \<3.2 represents LDA.
| percentage of participants | Tocilizumab |
|---|---|
| Week 28: Remission | 5.1 |
| Week 32: Remission | 8.1 |
| Week 36: Remission | 4.1 |
| Week 40: Remission | 9.5 |
| Week 44: Remission | 6.9 |
| Week 48: Remission | 8.5 |
| Week 52: Remission | 6 |
| Week 28: LDA | 7.6 |
| Week 32: LDA | 1.4 |
| Week 36: LDA | 6.8 |
| Week 40: LDA | 6.8 |
| Week 44: LDA | 6.9 |
| Week 48: LDA | 4.2 |
| Week 52: LDA | 9 |
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. A negative change from baseline indicates an improvement.
| units on a scale | Tocilizumab |
|---|---|
| Change at Week 2 | -0.99 (-1.33 to -0.64) |
| Change at Week 4 | -1.70 (-2.06 to -1.36) |
| Change at Week 8 | -2.20 (-2.54 to -1.84) |
| Change at Week 12 | -2.56 (-2.91 to -2.20) |
| Change at Week 16 | -2.59 (-2.91 to -2.27) |
| Change at Week 20 | -2.93 (-3.24 to -2.62) |
| Change at Week 24 | -3.14 (-3.45 to -2.83) |
| Change at Week 28 | -3.22 (-3.53 to -2.90) |
| Change at Week 32 | -3.34 (-3.66 to -3.01) |
| Change at Week 36 | -3.32 (-3.64 to -3.00) |
| Change at Week 40 | -3.40 (-3.73 to -3.07) |
| Change at Week 44 | -3.45 (-3.78 to -3.11) |
| Change at Week 48 | -3.42 (-3.76 to -3.08) |
| Change at Week 52 | -3.40 (-3.73 to -3.07) |
ACR20 response was defined as \>/=20% improvement from baseline in both TJC28 and SJC28 as well as in 3 out of 5 additional parameters: Separate patient and physician's global assessment of disease activity on VAS (0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS), patient's assessment of pain on VAS (0 mm=no pain to 100 mm=unbearable pain, displayed on the 100 mm horizontal VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI) (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without any difficulty to 3=unable to do), and acute phase response (ESR in mm/hr, for a total possible score of 0 to 10).
| participants | Tocilizumab |
|---|---|
| Week 2 | 19 |
| Week 4 | 19 |
| Week 8 | 23 |
| Week 12 | 9 |
| Week 16 | 13 |
| Week 20 | 16 |
| Week 24 | 9 |
| Week 28 | 13 |
| Week 32 | 10 |
| Week 36 | 11 |
| Week 40 | 10 |
| Week 44 | 12 |
| Week 48 | 13 |
| Week 52 | 15 |
Response to treatment was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the baseline visit. Participants with a score lesser than or equal to (\</=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \</=5.1 with reduction of \>0.6 to \</=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \</=1.2 points, or any score with reduction \</=0.6 points, were assessed as having 'no response'.
| percentage of participants | Tocilizumab |
|---|---|
| Week 2: Good response | 9.4 |
| Week 2: Moderate response | 44.8 |
| Week 2: No response | 45.8 |
| Week 4: Good response | 9.5 |
| Week 4: Moderate response | 38.9 |
| Week 4: No response | 51.6 |
| Week 8: Good response | 10.8 |
| Week 8: Moderate response | 23.6 |
| Week 8: No response | 65.6 |
| Week 12: Good response | 9.2 |
| Week 12: Moderate response | 20.7 |
| Week 12: No response | 70.1 |
| Week 16: Good response | 5.9 |
| Week 16: Moderate response | 15.3 |
| Week 16: No response | 78.8 |
| Week 20: Good response | 6.1 |
| Week 20: Moderate response | 26.8 |
| Week 20: No response | 67.1 |
| Week 24: Good response | 6.2 |
| Week 24: Moderate response | 21.2 |
| Week 24: No response | 72.6 |
| Week 28: Good response | 6.3 |
| Week 28: Moderate response | 11.4 |
| Week 28: No response | 82.3 |
| Week 32: Good response | 0 |
| Week 32: Moderate response | 18.9 |
| Week 32: No response | 81.1 |
| Week 36: Good response | 1.3 |
| Week 36: Moderate response | 14.9 |
| Week 36: No response | 83.8 |
| Week 40: Good response | 5.4 |
| Week 40: Moderate response | 17.6 |
| Week 40: No response | 77 |
| Week 44: Good response | 2.8 |
| Week 44: Moderate response | 13.9 |
| Week 44: No response | 83.3 |
| Week 48: Good response | 5.7 |
| Week 48: Moderate response | 11.4 |
| Week 48: No response | 82.9 |
| Week 52: Good response | 94 |
| Week 52: Moderate response | 6 |
| Week 52: No response | 0 |
SDAI is an index for measuring disease activity. SDAI is the numerical sum of five outcome parameters: TJC28 and SJC28, PGA and physician global assessment of disease activity assessed on VAS (0 centimeter \[cm\]-10 cm); 0 cm= no disease activity and 10 cm= worst disease activity, and CRP (in milligrams per deciliter \[mg/dL\]). SDAI total score ranges from 0 to 86, with higher scores indicating increased (or severe) disease activity. SDAI score \</=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Change at Week 2 | -3.41 (-7.17 to 0.12) |
| Change at Week 4 | -6.54 (-10.26 to -2.97) |
| Change at Week 8 | -8.72 (-12.89 to -5.18) |
| Change at Week 12 | -11.07 (-14.74 to -8.04) |
| Change at Week 16 | -13.47 (-17.00 to -10.60) |
| Change at Week 20 | -13.88 (-17.42 to -10.94) |
| Change at Week 24 | -14.08 (-17.72 to -11.25) |
| Change at Week 28 | -15.37 (-18.87 to -12.41) |
| Change at Week 32 | -16.09 (-19.63 to -13.07) |
| Change at Week 36 | -15.61 (-19.14 to -12.58) |
| Change at Week 40 | -14.86 (-18.66 to -11.84) |
| Change at Week 44 | -16.31 (-20.06 to -13.24) |
| Change at Week 48 | -16.47 (-20.13 to -13.45) |
| Change at Week 52 | -17.35 (-21.01 to -14.16) |
28 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 28. A negative change from baseline indicated improvement.
| tender joints | Tocilizumab |
|---|---|
| Change at Week 2 | -1.30 (-3.18 to 0.56) |
| Change at Week 4 | -3.26 (-5.09 to -1.42) |
| Change at Week 8 | -4.97 (-6.69 to -3.25) |
| Change at Week 12 | -5.82 (-7.55 to -4.09) |
| Change at Week 16 | -6.39 (-8.08 to -4.70) |
| Change at Week 20 | -7.03 (-8.67 to -5.38) |
| Change at Week 24 | -7.72 (-9.34 to -6.09) |
| Change at Week 28 | -7.91 (-9.51 to -6.31) |
| Change at Week 32 | -8.38 (-10.00 to -6.77) |
| Change at Week 36 | -8.28 (-9.86 to -6.66) |
| Change at Week 40 | -8.22 (-9.84 to -6.59) |
| Change at Week 44 | -8.63 (-10.25 to -7.01) |
| Change at Week 48 | -8.26 (-9.97 to -6.54) |
| Change at Week 52 | -8.75 (-10.41 to -7.09) |
28 joints were assessed for swelling and joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 28. A negative change from baseline indicated improvement.
| swollen joints | Tocilizumab |
|---|---|
| Change at Week 2 | -1.82 (-3.51 to -0.13) |
| Change at Week 4 | -3.08 (-4.70 to -1.46) |
| Change at Week 8 | -4.71 (-6.20 to -3.21) |
| Change at Week 12 | -5.24 (-6.68 to -3.79) |
| Change at Week 16 | -5.79 (-7.27 to -4.31) |
| Change at Week 20 | -6.06 (-7.55 to -4.57) |
| Change at Week 24 | -6.60 (-8.03 to -5.18) |
| Change at Week 28 | -6.65 (-8.09 to -5.21) |
| Change at Week 32 | -6.73 (-8.19 to -5.27) |
| Change at Week 36 | -6.76 (-8.22 to -5.28) |
| Change at Week 40 | -6.91 (-8.37 to -5.44) |
| Change at Week 44 | -6.82 (-8.31 to -5.33) |
| Change at Week 48 | -6.63 (-8.15 to -5.10) |
| Change at Week 52 | -6.98 (-8.52 to -5.44) |
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Corticosteroid Dose Reduction or Discontinuation | 48.6 |
Reasons for corticosteroid dose reduction included: Safety Reasons (including elevated liver function test results, respiratory infections, infections and infestations, gastrointestinal disorders etc.); Other Reasons (disease remission, improvement etc.); and Unknown Reasons (including no reason). Number of participants by reasons (Safety, Other, Unknown) for corticosteroid dose reduction or discontinuation were reported.
| participants | Tocilizumab |
|---|---|
| Safety | 6 |
| Other | 10 |
| Unknown | 2 |
All samples were tested using a screening assay and, if positive, by a confirmation assay to determine specificity and a neutralizing assay to test for the ability to inhibit the activity of tocilizumab. Number of participants with a positive assay result for screening assay (ATA - Screen), confirmatory assay (ATA - Confirmatory), and neutralizing assay (ATA - Neutralizing) was reported separately.
| participants | Tocilizumab |
|---|---|
| Week 1: ATA - Screen | 7 |
| Week 1: ATA - Confirmatory | 4 |
| Week 1: ATA - Neutralizing | 0 |
| Week 12: ATA - Screen | 3 |
| Week 12: ATA - Confirmatory | 0 |
| Week 12: ATA - Neutralizing | 0 |
| Week 24: ATA - Screen | 3 |
| Week 24: ATA - Confirmatory | 1 |
| Week 24: ATA - Neutralizing | 1 |
| Week 36: ATA - Screen | 2 |
| Week 36: ATA - Confirmatory | 0 |
| Week 36: ATA - Neutralizing | 0 |
| Week 52: ATA - Screen | 2 |
| Week 52: ATA - Confirmatory | 0 |
| Week 52: ATA - Neutralizing | 0 |
| Week 60: ATA - Screen | 1 |
| Week 60: ATA - Confirmatory | 1 |
| Week 60: ATA - Neutralizing | 0 |
| nanograms per milliliter (ng/mL) | Tocilizumab |
|---|---|
| Week 1 | 39450 ± 10740 |
| Week 12 | 553.43 ± 120.36 |
| Week 24 | 572.03 ± 136.68 |
| Week 36 | 570.78 ± 139.16 |
| Week 52 | 537.73 ± 152.55 |
| Week 60 | 42850 ± 13800 |
| microgrms per milliliter (mcg/mL) | Tocilizumab |
|---|---|
| Week 1 | 0.38 ± 0.17 |
| Week 12 | 41.98 ± 25.04 |
| Week 24 | 44.67 ± 28.83 |
| Week 36 | 47.90 ± 28.29 |
| Week 52 | 45.37 ± 28.13 |
| Week 60 | 6.46 ± 4.28 |
PGA was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end = 100 mm, and was described as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).
| mm | Tocilizumab |
|---|---|
| Week 1 | 28.26 ± 20.25 |
| Week 2 | 27.57 ± 20.08 |
| Week 4 | 28.36 ± 19.37 |
| Week 8 | 32.28 ± 22.09 |
| Week 12 | 28.73 ± 23.01 |
| Week 16 | 24.40 ± 19.02 |
| Week 20 | 28.15 ± 20.22 |
| Week 24 | 32.63 ± 23.44 |
| Week 28 | 26.02 ± 18.79 |
| Week 32 | 27.08 ± 20.98 |
| Week 36 | 30.79 ± 22.37 |
| Week 40 | 30.50 ± 21.93 |
| Week 44 | 25.79 ± 16.33 |
| Week 48 | 23.86 ± 19.11 |
| Week 52 | 23.08 ± 17.08 |
The participant's level of pain was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as "no pain" and the extreme right end = 100 mm, and was described as "unbearable pain". Higher values correspond to worst state of participant (higher level of pain).
| mm | Tocilizumab |
|---|---|
| Week 1 | 46.40 ± 27.43 |
| Week 2 | 52.04 ± 24.46 |
| Week 4 | 49.87 ± 23.35 |
| Week 8 | 42.72 ± 23.20 |
| Week 12 | 37.21 ± 21.29 |
| Week 16 | 34.24 ± 22.49 |
| Week 20 | 31.00 ± 19.42 |
| Week 24 | 29.57 ± 19.66 |
| Week 28 | 29.63 ± 19.07 |
| Week 32 | 25.50 ± 17.95 |
| Week 36 | 26.78 ± 22.13 |
| Week 40 | 27.50 ± 21.93 |
| Week 44 | 26.88 ± 19.96 |
| Week 48 | 23.61 ± 18.63 |
| Week 52 | 23.98 ± 20.19 |
The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set were scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person was required. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent "mild to moderate difficulty", 1 to 2 as "moderate to severe disability", and 2 to 3 as "severe to very severe disability".
| units on a scale | Tocilizumab |
|---|---|
| Week 1 | 1.31 ± 0.66 |
| Week 2 | 1.22 ± 0.64 |
| Week 4 | 1.09 ± 0.66 |
| Week 8 | 0.91 ± 0.66 |
| Week 12 | 0.82 ± 0.58 |
| Week 16 | 0.72 ± 0.59 |
| Week 20 | 0.68 ± 0.56 |
| Week 24 | 0.66 ± 0.55 |
| Week 28 | 0.66 ± 0.57 |
| Week 32 | 0.59 ± 0.58 |
| Week 36 | 0.63 ± 0.58 |
| Week 40 | 0.60 ± 0.59 |
| Week 44 | 0.59 ± 0.61 |
| Week 48 | 0.56 ± 0.59 |
| Week 52 | 0.54 ± 0.60 |
Compliance (in terms of percentage of participants who received all planned study medication) was assessed on the basis of participant diary cards and return records.
| percentage of participants | Tocilizumab |
|---|---|
| Week 1 | 66 |
| Week 2 | 97.9 |
| Week 4 | 100 |
| Week 8 | 100 |
| Week 12 | 98.9 |
| Week 16 | 97.6 |
| Week 20 | 98.8 |
| Week 24 | 100 |
| Week 28 | 100 |
| Week 32 | 100 |
| Week 36 | 100 |
| Week 40 | 100 |
| Week 44 | 100 |
| Week 48 | 100 |
| Week 52 | 100 |
FACIT-Fatigue total score is sum of FACIT-General subscale score and FACIT-Fatigue (additional concerns) subscale score. FACT-General consists of 27 questions grouped in 4 domains of general health-related quality of life: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-General score ranges between 0-108. FACIT-Fatigue subscale is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). For all items, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue subscale score for a total possible score of 0 (worse score) to 52 (better score). FACIT-Fatigue total score (FACT-G plus FACT-F subscale scores) ranges from 0 (better score) to 160 (worse score).
| units on a scale | Tocilizumab |
|---|---|
| Week 1 | 89.68 ± 24.32 |
| Week 2 | 91.83 ± 22.91 |
| Week 4 | 100.38 ± 24.36 |
| Week 8 | 103.16 ± 26.28 |
| Week 12 | 106.39 ± 24.74 |
| Week 16 | 110.17 ± 24.96 |
| Week 20 | 112.60 ± 25.50 |
| Week 24 | 114.21 ± 25.23 |
| Week 28 | 114.85 ± 26.95 |
| Week 32 | 117.01 ± 26.00 |
| Week 36 | 116.50 ± 26.17 |
| Week 40 | 116.59 ± 26.20 |
| Week 44 | 119.67 ± 26.64 |
| Week 48 | 119.83 ± 26.51 |
| Week 52 | 121.82 ± 25.34 |
Collected over From Baseline up to end of study (Week 60). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab Monotherapy | — | 2/31 (6.5%) | 19/31 (61.3%) |
| Tocilizumab + Methotrexate or Other Non-Biologic DMARDs | — | 5/66 (7.6%) | 38/66 (57.6%) |
| Event | Tocilizumab Monotherapy | Tocilizumab + Methotrexate or Other Non-Biologic DMARDs |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/31 | 1/66 |
| Respiratory tract infectionInfections and infestations | 1/31 | 0/66 |
| DehydrationMetabolism and nutrition disorders | 1/31 | 0/66 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/31 | 2/66 |
| Acute coronary syndromeCardiac disorders | 0/31 | 1/66 |
| Pancreatitis acuteGastrointestinal disorders | 0/31 | 1/66 |
| BronchitisInfections and infestations | 0/31 | 1/66 |
| Event | Tocilizumab Monotherapy | Tocilizumab + Methotrexate or Other Non-Biologic DMARDs |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 9/31 | 13/66 |
| Aspartate aminotransferase increasedInvestigations | 8/31 | 9/66 |
| NeutropeniaBlood and lymphatic system disorders | 6/31 | 5/66 |
| PruritusSkin and subcutaneous tissue disorders | 5/31 | 4/66 |
| LeukopeniaBlood and lymphatic system disorders | 4/31 | 8/66 |
| NauseaGastrointestinal disorders | 4/31 | 0/66 |
| NasopharyngitisInfections and infestations | 4/31 | 8/66 |
| BronchitisInfections and infestations | 3/31 | 5/66 |
| ContusionInjury, poisoning and procedural complications | 3/31 | 2/66 |
| Blood triglycerides increasedInvestigations | 3/31 | 3/66 |
Full analysis set included all recruited participants who received at least one dose of SC tocilizumab.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 56.27 ± 12.77 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 86 |
| Male | 11 |
Ran from Nov 2013 to primary completion in Jul 2016, 31 months.
Results were first posted in Nov 2018, 2 years 4 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 31 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Tocilizumab